Callyope is a brand that utilizes vocal biomarkers to monitor brain health through speech. With a focus on psychiatry, Callyope offers an innovative and objective tool for tracking the progression of psychiatric disorders. Whether it's in the clinic or at home, their voice-based technology provides a replicable way to monitor patients' conditions.

Callyope is committed to improving patient monitoring in psychiatry by addressing the challenges faced by both patients and healthcare providers. They strive to enhance the quality of care by shortening the time it takes to find the right treatment, adjusting treatment as necessary, and preventing relapses to minimize rehospitalization. The process is simple: patients perform a quick 1-minute voice test on their smartphones, eliminating the need for a baseline assessment.

Callyope's sophisticated technology analyzes the patient's speech to predict psychiatric clinical scores, assess fatigue levels, and estimate cognition deficits. And the best part? It works for unknown speakers, making it a versatile solution. With 1 in 5 Europeans suffering from mental health disorders, Callyope's mission is especially impactful.

They aim to make a difference by providing innovative technology that helps improve patients' lives. Supported by a team of experienced founders, scientific and clinical advisors, and cutting-edge research, Callyope's brand is paving the way for advancements in mental healthcare